Literature DB >> 19141267

ACE inhibitors and ARBs: one or the other--not both--for high-risk patients.

Shamita Misra1, James J Stevermer.   

Abstract

Entities:  

Year:  2009        PMID： 19141267      PMCID： PMC3183919     

Source DB:  PubMed          Journal:  J Fam Pract        ISSN： 0094-3509            Impact factor:   0.493


× No keyword cloud information.
  7 in total

1.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

2.  A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.

Authors:  J N Cohn; G Tognoni
Journal:  N Engl J Med       Date:  2001-12-06       Impact factor: 91.245

3.  Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study.

Authors:  C E Mogensen; S Neldam; I Tikkanen; S Oren; R Viskoper; R W Watts; M E Cooper
Journal:  BMJ       Date:  2000-12-09

4.  Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial.

Authors:  Naoyuki Nakao; Ashio Yoshimura; Hiroyuki Morita; Masyuki Takada; Tsuguo Kayano; Terukuni Ideura
Journal:  Lancet       Date:  2003-01-11       Impact factor: 79.321

5.  Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.

Authors:  Johannes F E Mann; Roland E Schmieder; Matthew McQueen; Leanne Dyal; Helmut Schumacher; Janice Pogue; Xingyu Wang; Aldo Maggioni; Andrzej Budaj; Suphachai Chaithiraphan; Kenneth Dickstein; Matyas Keltai; Kaj Metsärinne; Ali Oto; Alexander Parkhomenko; Leopoldo S Piegas; Tage L Svendsen; Koon K Teo; Salim Yusuf
Journal:  Lancet       Date:  2008-08-16       Impact factor: 79.321

6.  Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis.

Authors:  D L Jennings; J S Kalus; C I Coleman; C Manierski; J Yee
Journal:  Diabet Med       Date:  2007-03-15       Impact factor: 4.359

7.  Telmisartan, ramipril, or both in patients at high risk for vascular events.

Authors:  Salim Yusuf; Koon K Teo; Janice Pogue; Leanne Dyal; Ingrid Copland; Helmut Schumacher; Gilles Dagenais; Peter Sleight; Craig Anderson
Journal:  N Engl J Med       Date:  2008-03-31       Impact factor: 91.245
  7 in total
  3 in total

Review 1.  The renin-angiotensin system biomolecular cascade: a 2022 update of newer insights and concepts.

Authors:  Carlos M Ferrario; Leanne Groban; Hao Wang; Xuming Sun; Jessica L VonCannon; Kendra N Wright; Sarfaraz Ahmad
Journal:  Kidney Int Suppl (2011)       Date:  2022-03-18

2.  Alterations in Gene Expression of Renin-Angiotensin System Components and Related Proteins in Colorectal Cancer.

Authors:  Danial Mehranfard; Gabriela Perez; Andres Rodriguez; Julia M Ladna; Christopher T Neagra; Benjamin Goldstein; Timothy Carroll; Alice Tran; Malav Trivedi; Robert C Speth
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2021-07-05       Impact factor: 1.636

3.  Inhibition of Angiotensin Converting Enzyme Impairs Anti-staphylococcal Immune Function in a Preclinical Model of Implant Infection.

Authors:  Rishi Trikha; Danielle Greig; Benjamin V Kelley; Zeinab Mamouei; Troy Sekimura; Nicolas Cevallos; Thomas Olson; Ameen Chaudry; Clara Magyar; Daniel Leisman; Alexandra Stavrakis; Michael R Yeaman; Nicholas M Bernthal
Journal:  Front Immunol       Date:  2020-09-11       Impact factor: 7.561
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.